CO5550417A2 - Formulacion farmaceutica que comprende un inhibidor de bomba de proton y antiacidos - Google Patents

Formulacion farmaceutica que comprende un inhibidor de bomba de proton y antiacidos

Info

Publication number
CO5550417A2
CO5550417A2 CO04002774A CO04002774A CO5550417A2 CO 5550417 A2 CO5550417 A2 CO 5550417A2 CO 04002774 A CO04002774 A CO 04002774A CO 04002774 A CO04002774 A CO 04002774A CO 5550417 A2 CO5550417 A2 CO 5550417A2
Authority
CO
Colombia
Prior art keywords
microgranules
pump inhibitor
proton
agent
coated
Prior art date
Application number
CO04002774A
Other languages
English (en)
Inventor
Bruno Criere
Nourredine Nouri
Pascal Suplie
Jean-Mare Zuccarelli
Ake Pilbrant
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5550417A2 publication Critical patent/CO5550417A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Tableta de multiparticula que se desintegra en la boca y que contiene:i) Un agente inhibidor de bomba de protón, en particular del tipo benzimidazole, en forma de microgránulos en capas de recubrimiento entérico que son recubiertos con al menos un recubrimiento de barrera que proteja el recubrimiento entérico de la disolución y/o desintegración durante el transporte de los microgránulos al intestino delgado; ii) Al menos un antiácido en forma de gránulos, y; iii) Una mezcla de excipientes que comprenden al menos un agente desintegrador, un agente diluyente y un lubricante.33.- El proceso para la fabricación de una tableta según cualquiera de las reivindicaciones 1 a 32, caracterizadas porque el inhibidor de bomba de protón se prepara en forma de microgránulos con recubrimiento entérico que son recubiertos por rociado con una capa barrera y mezclados con los gránulos del antiácido y una mezcla del agente desintegrador, el agente diluyente y un lubricante.
CO04002774A 2001-07-16 2004-01-16 Formulacion farmaceutica que comprende un inhibidor de bomba de proton y antiacidos CO5550417A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01401896 2001-07-16

Publications (1)

Publication Number Publication Date
CO5550417A2 true CO5550417A2 (es) 2005-08-31

Family

ID=8182807

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04002774A CO5550417A2 (es) 2001-07-16 2004-01-16 Formulacion farmaceutica que comprende un inhibidor de bomba de proton y antiacidos

Country Status (24)

Country Link
US (2) US20040219211A1 (es)
EP (1) EP1416922A1 (es)
JP (1) JP2004536855A (es)
KR (1) KR20040018463A (es)
CN (1) CN100469366C (es)
AR (1) AR034757A1 (es)
AU (1) AU2002316020B2 (es)
BG (1) BG108515A (es)
BR (1) BR0211117A (es)
CA (1) CA2453290A1 (es)
CO (1) CO5550417A2 (es)
HU (1) HUP0401941A3 (es)
IL (1) IL159584A0 (es)
IS (1) IS7111A (es)
MX (1) MXPA04000385A (es)
MY (1) MY136137A (es)
NO (1) NO20040178L (es)
NZ (1) NZ530511A (es)
PL (1) PL367686A1 (es)
RU (1) RU2301662C2 (es)
UA (1) UA75673C2 (es)
UY (1) UY27385A1 (es)
WO (1) WO2003007917A1 (es)
ZA (1) ZA200400285B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596101A (zh) 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 含有糖果组分的剂型
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
CN100438914C (zh) * 2003-10-15 2008-12-03 富士化学工业株式会社 用于口腔内快速崩解的片剂的组合物
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
US20070082047A1 (en) * 2003-11-07 2007-04-12 Masae Sugaya Solid preparation
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
EP1621187A1 (en) * 2004-07-26 2006-02-01 AstraZeneca AB Pharmaceutical multiparticulate tablet formulations and process for their preparation
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
US8057820B2 (en) 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
CN100431526C (zh) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 一种酸敏感型药物的快速崩解片剂
CN101120930B (zh) * 2006-08-11 2010-09-29 石药集团中奇制药技术（石家庄）有限公司 一种奥美拉唑组合物及其制备方法
WO2009086942A1 (en) * 2008-01-10 2009-07-16 Evonik Röhm Gmbh Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
TR201902212T4 (tr) 2008-01-10 2019-06-21 Evonik Roehm Gmbh Geli̇şmi̇ş deği̇şken dozlu akti̇f madde salimina sahi̇p kapli farmasöti̇k veya nutrasöti̇k preparat
RU2497503C9 (ru) * 2008-03-10 2014-09-20 Байер Конзюмер Кер АГ Приятная на вкус твердая композиция, включающая нейтрализатор кислотности и стимулятор слюноотделения
GEP20135845B (en) 2008-03-11 2013-06-10 Takeda Pharmaceutical Orally-disintegrating solid formulation
MX2011004744A (es) * 2008-11-17 2011-05-30 Nycomed Pharma As Estabilidad mejorada de disolucion de tabletas de carbonato de calcio.
KR101908748B1 (ko) * 2010-12-03 2018-10-16 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴정
CN102085188B (zh) * 2011-01-14 2013-01-02 寿光富康制药有限公司 一种兰索拉唑肠溶微丸的制备方法
CN102078616A (zh) * 2011-01-28 2011-06-01 北京虹湾医药技术有限公司 埃索美拉唑碳酸氢钠组合物
US8277842B1 (en) * 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
CN102631327B (zh) * 2012-05-14 2013-08-28 海南葫芦娃制药有限公司 一种奥美拉唑肠溶微丸及其制备方法
CN103479593B (zh) * 2013-05-10 2014-10-08 青岛双鲸药业有限公司 一种奥美拉唑肠溶片的制备方法
JP6156037B2 (ja) * 2013-10-03 2017-07-05 ライオン株式会社 固形医薬製剤組成物
CN103784414B (zh) * 2013-12-18 2018-01-30 北京华禧联合科技发展有限公司 一种埃索美拉唑肠溶片及其制备方法
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CA3010778C (en) * 2016-02-03 2024-02-27 Novartis Ag Galenic formulations of organic compounds
US20190151297A1 (en) * 2016-04-29 2019-05-23 Nauts Equine Brand Pty Ltd Veterinary Composition
US10076494B2 (en) * 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108434117A (zh) * 2018-03-29 2018-08-24 成都通德药业有限公司 一种奥美拉唑肠溶胶囊的制备方法
RU2727506C1 (ru) * 2019-09-09 2020-07-22 Пивипи Лабс Пте. Лтд. Средство для лечения эректильной дисфункции
CN114980867B (zh) * 2020-01-23 2024-03-15 韩美药品株式会社 包含质子泵抑制剂和抗酸剂的药物复合制剂
KR20220065997A (ko) * 2020-11-13 2022-05-23 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
CN114617852B (zh) * 2020-12-10 2023-06-27 昆药集团股份有限公司 一种奥美拉唑肠溶制剂及其制备方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2516408B2 (ja) * 1988-08-18 1996-07-24 エスエス製薬株式会社 被覆顆粒を含む錠剤
DE4122217C2 (de) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
EP0723436B1 (en) * 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
DE19617487A1 (de) * 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
JP3961596B2 (ja) * 1996-10-15 2007-08-22 富士化学工業株式会社 無機制酸剤含有速分散性造粒物、その製造方法及び用時懸濁内服制酸剤
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
US6328994B1 (en) * 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
WO2000078292A1 (fr) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Preparations solides a desintegration rapide
DE19954653B4 (de) * 1999-11-13 2006-01-19 Contitech Profile Gmbh Extruder zur Aufbereitung von Kautschukmischungen
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
ATE541564T1 (de) * 2000-12-07 2012-02-15 Nycomed Gmbh Schnell zerfallende tablette mit einem säurelabilen wirkstoff

Also Published As

Publication number Publication date
MY136137A (en) 2008-08-29
UY27385A1 (es) 2003-02-28
ZA200400285B (en) 2005-06-29
UA75673C2 (en) 2006-05-15
WO2003007917A1 (en) 2003-01-30
CN100469366C (zh) 2009-03-18
PL367686A1 (en) 2005-03-07
KR20040018463A (ko) 2004-03-03
AU2002316020B2 (en) 2007-03-15
BR0211117A (pt) 2004-06-22
CA2453290A1 (en) 2003-01-30
RU2004101061A (ru) 2005-04-20
NO20040178L (no) 2004-03-16
HUP0401941A3 (en) 2008-04-28
IL159584A0 (en) 2004-06-01
CN1555256A (zh) 2004-12-15
HUP0401941A2 (hu) 2005-01-28
RU2301662C2 (ru) 2007-06-27
EP1416922A1 (en) 2004-05-12
US20110135722A1 (en) 2011-06-09
IS7111A (is) 2004-01-15
NZ530511A (en) 2005-06-24
AR034757A1 (es) 2004-03-17
BG108515A (en) 2005-02-28
US20040219211A1 (en) 2004-11-04
JP2004536855A (ja) 2004-12-09
MXPA04000385A (es) 2004-05-04

Similar Documents

Publication Publication Date Title
CO5550417A2 (es) Formulacion farmaceutica que comprende un inhibidor de bomba de proton y antiacidos
ES2496102T3 (es) Forma de dosificación oral sólida que contiene microcápsulas sin fisuras
AR018143A1 (es) Formulacion para preparar un comprimido de desintegracion rapida, comprimidos de desintegracion rapida, especialmente comprimidos de desintegracionrapida en la boca
AR024384A1 (es) UNA FORMA DE DOSIFICACIoN FARMACÉUTICA DE DISOLUCIoN INSTANTÁNEA Y UN MÉTODO PARA PREPARARLA
CA2146637C (en) Pharmaceutical compositions and methods for treating cold symptoms
Roge et al. The enkephalinase inhibitor, acetorphan, in acute diarrhoea: a double-blind, controlled clinical trial versus loperamide
CO5560548A2 (es) Formulaciones de deposito oftalmicas para administracion periocular o subconjuntival
PE20020529A1 (es) Forma de dosificacion farmaceutica con multiples recubrimientos para reducir el impacto de fracturas del recubrimiento
AR020850A1 (es) Tratamiento de bph con agentes elevadores del cgmp
AR041370A1 (es) Formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
JP2004536855A5 (es)
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
EA200501001A1 (ru) Фармацевтический состав с нерастворимым активным агентом
CO5640086A2 (es) Formulacion agonistas opioide con antagonistas liberables y secuestrados
CO6721054A2 (es) Tableta oralmente desintegradora
ES2194704T3 (es) Comprimido dispersable oralmente que presenta una debil friabilidad y su procedimiento de preparacion.
AR008553A1 (es) Forma de dosificacion farmaceutica que enmascara el sabor y que se libera rapidamente.
AR043258A1 (es) Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica
PE71699A1 (es) Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
AR038899A1 (es) Un medicamento para animales
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
ES2207466T3 (es) Comprimido farmaceutico que comprende nsaid y misoprostol.
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
AR002049A1 (es) Una composicion farmaceutica para la administracion oral de agentes activos que tienen baja solubilidad en agua y el procedimiento para prepararla
AR037356A1 (es) Forma de dosificacion oral de una prodroga de sulfonamida

Legal Events

Date Code Title Description
FC Application refused